SNS-314 Mesylate: A Selective Pan-Aurora Kinase Inhibitor with Promising Anticancer Activity

 Introduction

SNS-314 mesylate (CAS 1146618-41-8) is a small molecule drug candidate designed to inhibit Aurora kinases A, B, and C with high potency. This compound is attracting attention in oncology research due to its ability to disrupt cancer cell division and slow tumor progression.

Key Highlights

  • Broad Aurora Kinase Inhibition: SNS-314 effectively blocks Aurora kinases at low nanomolar concentrations, showing strong selectivity over unrelated kinases.

  • Mechanism of Action: The compound disrupts mitotic spindle formation and cytokinesis, leading to cell cycle arrest, DNA re-replication, and programmed cell death in tumor cells.

  • Antitumor Efficacy: Preclinical studies demonstrate that SNS-314 significantly reduces tumor growth, both as a single agent and in combination with standard chemotherapies such as docetaxel and vincristine.

  • Clinical Development: Early-phase clinical trials are underway to explore the safety, tolerability, and pharmacokinetics of SNS-314 in patients with advanced solid tumors.

Conclusion
SNS-314 mesylate stands out as a potent pan-Aurora kinase inhibitor with compelling anticancer properties. Its synergy with existing therapies highlights its potential to become part of future combination treatments for various cancers.

SEO Keywords: SNS-314 mesylate, Aurora kinase inhibitor, CAS 1146618-41-8, antitumor activity, preclinical research, oncology drug candidate, clinical trials.

2. Article (In-Depth Analysis)

Title: SNS-314 Mesylate (CAS 1146618-41-8): A Pan-Aurora Kinase Inhibitor with Multi-Modal Anticancer Capabilities

Abstract
SNS-314 mesylate is an investigational anticancer compound that acts as a selective, ATP-competitive inhibitor of Aurora kinases A, B, and C. With demonstrated antitumor activity in preclinical models and entry into early clinical trials, it represents a promising new strategy in oncology drug development.

1. Molecular Profile

SNS-314 inhibits Aurora kinases at nanomolar potency levels, showing strong activity against Aurora A, B, and C. It is selective against these targets while sparing most other kinases, which enhances its therapeutic potential.

2. Mechanism of Action

By interfering with Aurora kinase activity, SNS-314 halts proper chromosome segregation during mitosis. This results in cytokinesis failure, polyploidy, and eventual apoptosis of cancer cells. Such disruption is particularly effective in rapidly dividing tumors.

3. Preclinical Antitumor Activity

In preclinical xenograft models, SNS-314 has shown dose-dependent inhibition of tumor growth. It also enhances the efficacy of established chemotherapeutic agents, demonstrating additive and synergistic effects when combined with drugs such as docetaxel, vincristine, or gemcitabine.

4. Technical Specifications

The compound is supplied as a mesylate salt, with a molecular weight of approximately 527 Da. It is typically provided at high purity and is soluble in DMSO but poorly soluble in water. Standard laboratory storage conditions maintain its stability for research use.

5. Clinical Development

SNS-314 has advanced to Phase 1 clinical trials, where its safety, tolerability, and dosing schedule are under evaluation in patients with advanced solid tumors. These studies aim to determine optimal therapeutic use and explore its potential in combination regimens.

Conclusion
SNS-314 mesylate is emerging as an important investigational compound in cancer research. Its potent inhibition of Aurora kinases, proven activity in preclinical tumor models, and ability to enhance the effects of existing drugs make it a strong candidate for future oncology therapies. Ongoing clinical development will determine its role in targeted cancer treatment strategies.

Comments

Post a Comment

Popular posts from this blog

D-Leu7-Triptorelin (CAS 321709-37-9) | Peptide Impurity Standard by Pharmaffiliates

Image
D-Leu7-Triptorelin (CAS 321709-37-9) | Peptide Impurity Standard by Pharmaffiliates D-Leu7-Triptorelin, identified by CAS number 321709-37-9 , is a synthetic peptide categorized as an in-house impurity and research-grade reference material. It is structurally related to the well-known GnRH analogue Triptorelin , a peptide used in hormonal and oncology research. Unlike the parent compound, D-Leu7-Triptorelin is primarily intended for laboratory, analytical, and reference purposes rather than therapeutic use. Chemical Profile and Specifications Chemical Name: Glycinamide, 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-D-leucyl-L-arginyl-L-prolyl Molecular Formula: C₆₄H₈₂N₁₈O₁₃ Molecular Weight: 1311.47 g/mol Product Code: PA PEP 003537 Category: Peptides / Reference Standards Storage Condition: 2-8 °C (Refrigerator) Shipping Condition: Ambient These precise attributes help researchers and analytical laboratories maintain consistency in peptide test...
Read more

CAS 2857963-60-9: Premium Peptide Reference Standard for Advanced Research & QC

Image
CAS 2857963-60-9: Premium Peptide Reference Standard for Advanced Research & QC CAS 2857963-60-9, also known as 3,6,9,12,15,18,21,24,27,30-Decamethyl-4,7,10,13,16,19,22,25,28,31-decaoxo-3,6,9,12,15,18,21,24,27,30-decaazadotriacontanoic acid , represents a highly specialized peptide-based reference compound widely utilized in pharmaceutical research, analytical testing, and peptide formulation development. Due to its extended chain length and multiple carbonyl-amide functional groups, this molecule plays a key role in validating purification protocols, analyzing peptide impurities, and studying long-chain peptide analogs. This compound is especially valuable in R&D facilities, peptide synthesis laboratories, CROs, CDMOs, and regulated pharmaceutical environments , where accuracy, traceability, and certified quality standards are critical. Chemical Profile & Structure CAS Number 2857963-60-9 Chemical Nature Long-chain poly-peptide analog Functional Groups Carbonyl, amide...
Read more

Exploring D-Leu-4-OB3 (CAS 289056-32-2): A Key Research Peptide with Scientific Potential

Image
Exploring D-Leu-4-OB3 (CAS 289056-32-2): A Key Research Peptide with Scientific Potential Pharmaffiliates Private Limited lists D-Leu-4-OB3 under catalogue number PA PEP 003427 , with the CAS number 289056-32-2 . This compound falls under the “Peptides” category on the Pharmaffiliates website and is offered primarily for research purposes . The chemical name of the compound is: L-Threonine, L-seryl-L-cysteinyl-L-seryl-D-leucyl-L-prolyl-L-glutaminyl-; L-seryl-L-cysteinyl-L-seryl-D-leucyl-L-prolyl-L-glutaminyl-L-threonine; Mus musculus [D-Leu-4]-OB3 peptide; Mouse [D-Leu-4]-OB3. Its molecular formula is C₂₉H₅₀N₈O₁₂S , with a molecular weight of 734.82 g/mol . The product page specifies storage conditions of 2-8 °C with ambient shipping . These details ensure that researchers are aware of both the storage and handling requirements of the compound. Composition and Structure D-Leu-4-OB3 is a synthetic research peptide that contains both L- and D-amino acids . The “D-Leu” part of t...
Read more